Amgen Q3 2022 Earnings Report
Key Takeaways
Amgen's Q3 2022 financial results showed a slight decrease in total revenues, but an increase in both GAAP and non-GAAP EPS. The company's medicines generated 8% volume growth globally, with 11 products achieving record quarterly sales. The company revised its 2022 total revenues guidance to $26.0-$26.3 billion and EPS guidance to $11.46-$12.17 on a GAAP basis, and $17.25-$17.85 on a non-GAAP basis.
Total revenues decreased 1% to $6.7 billion, impacted by lower net selling prices and foreign exchange.
GAAP EPS increased from $3.31 to $3.98, and non-GAAP EPS increased from $4.08 to $4.70, driven by decreased operating expenses and lower weighted-average shares outstanding.
Free cash flow increased to $2.8 billion compared to $2.2 billion in the third quarter of 2021.
Volume growth was strong for several products, including EVENITY, Repatha, and Vectibix.
Amgen
Amgen
Amgen Revenue by Segment
Forward Guidance
For the full year 2022, the company expects total revenues in the range of $26.0 billion to $26.3 billion. On a GAAP basis, EPS is expected in the range of $11.46 to $12.17, and a tax rate in the range of 11.0% to 12.5%. On a non-GAAP basis, EPS is expected in the range of $17.25 to $17.85, and a tax rate in the range of 13.5% to 14.5%.
Positive Outlook
- Total revenues in the range of $26.0 billion to $26.3 billion.
- GAAP EPS in the range of $11.46 to $12.17.
- GAAP tax rate in the range of 11.0% to 12.5%.
- Non-GAAP EPS in the range of $17.25 to $17.85.
- Non-GAAP tax rate in the range of 13.5% to 14.5%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income